Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

Aiming for a new indication to expand the use — and sales — of its psoriatic arthritis drug Taltz, Eli Lilly is spotlighting positive Phase III results Thursday for its blockbuster hopeful against another type of arthritis: ankylosing spondylitis.